The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Cancer drug targets uncovered using base editing and chemical proteomics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A team at Scripps Research and the Broad Institute of Harvard and MIT has discovered a new method to hone in on new drug targets most likely to impact multiple cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Clinical Roundup

Study reveals dog and human cancers are more similar than previously known

Researchers from the Broad Institute of MIT and Harvard, the University of Georgia, and the One Health Company have published the results from the largest-ever genomic sequencing study of canine tumors. The study shows that dog and human cancers are far more genetically similar than previously known and underscores the important role of canine cancer data in accelerating the development of precision treatments for cancer patients of both species.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account